These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29997939)

  • 1. ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what's up?
    Depypere LP; Vervloet G; Lerut T; Moons J; De Hertogh G; Sagaert X; Coosemans W; Van Veer H; Nafteux PR
    J Thorac Dis; 2018 May; 10(5):2771-2778. PubMed ID: 29997939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ypT0N+ status in oesophageal cancer patients: Location of residual metastatic lymph nodes with regard to the neoadjuvant radiation field.
    Schurink B; Seesing MFJ; Goense L; Mook S; Brosens LAA; Mohammad NH; Ruurda JP; Roeling TAP; Bleys RLAW; van Hillegersberg R
    Eur J Surg Oncol; 2019 Mar; 45(3):454-459. PubMed ID: 30503227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study.
    Al-Kaabi A; van der Post RS; van der Werf LR; Wijnhoven BPL; Rosman C; Hulshof MCCM; van Laarhoven HWM; Verhoeven RHA; Siersema PD
    Acta Oncol; 2021 Apr; 60(4):497-504. PubMed ID: 33491513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinoma.
    Park SY; Lee J; Oh D; Sun JM; Yun J; Jeon YJ; Cho JH; Choi YS; Zo JI; Shim YM; Kim HK
    Esophagus; 2024 Jan; 21(1):51-57. PubMed ID: 38082188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual lymph node disease and mortality following neoadjuvant chemoradiation and curative esophagectomy for distal esophageal adenocarcinoma.
    Kandilis A; Iniguez CB; Khalil H; Mazzola E; Jaklitsch MT; Swanson SJ; Bueno R; Wee JO
    JTCVS Open; 2021 Mar; 5():135-147. PubMed ID: 36003158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
    Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent prognosis with no lymph node metastasis to pathological complete remission in patients with localized advanced esophageal cancer after neoadjuvant triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by curative surgery: a single-center retrospective cohort study.
    Chinen T; Yamaguchi H; Ohzawa H; Matsumoto S; Kurashina K; Saito S; Hosoya Y; Fujii H; Kitayama J; Sata N
    J Thorac Dis; 2024 Jan; 16(1):391-400. PubMed ID: 38410613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer.
    Vollenbrock SE; van Dieren JM; Voncken FEM; van Turenhout ST; Kodach LL; Hartemink KJ; van Sandick JW; Aleman BMP; Beets-Tan RGH; Bartels-Rutten A
    Eur Radiol; 2020 May; 30(5):2425-2434. PubMed ID: 31965258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of residual nodal involvement after complete tumor response in patients undergoing neoadjuvant (chemo)radiotherapy for rectal cancer.
    Erkan A; Mendez A; Trepanier M; Kelly J; Nassif G; Albert MR; Lee L; Monson JRT
    Surgery; 2019 Oct; 166(4):648-654. PubMed ID: 31378480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma.
    Park SY; Kim HK; Jeon YJ; Lee J; Cho JH; Choi YS; Shim YM; Zo JI
    Cancer Res Treat; 2023 Oct; 55(4):1231-1239. PubMed ID: 37114475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes in patients with ypT0 rectal cancer after neoadjuvant chemoradiotherapy and curative resection.
    Lu Z; Cheng P; Yang F; Zheng Z; Wang X
    Chin J Cancer Res; 2018 Apr; 30(2):272-281. PubMed ID: 29861612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Extracapsular Lymph Node Involvement After Neoadjuvant Chemoradiation Therapy Followed by Surgery in Carcinoma of the Esophagus: A Multicenter Study.
    Depypere LP; Moons J; Mariette C; D'Journo XB; Thomas PA; Hölscher AH; Bollschweiler E; van Berge-Henegouwen MI; Van Lanschot JJB; Lerut TEMR; Nafteux PR
    Ann Surg; 2018 Dec; 268(6):1000-1007. PubMed ID: 28742714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
    Zanoni A; Verlato G; Giacopuzzi S; Motton M; Casella F; Weindelmayer J; Ambrosi E; Di Leo A; Vassiliadis A; Ricci F; Rice TW; de Manzoni G
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):998-1004. PubMed ID: 27480358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.
    Burt BM; Groth SS; Sada YH; Farjah F; Cornwell L; Sugarbaker DJ; Massarweh NN
    Ann Surg; 2017 Aug; 266(2):297-304. PubMed ID: 27501170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemoradiation treatment followed by surgery for esophageal cancer: there is much more than the mandard tumor regression score.
    Depypere L; Moons J; Lerut T; De Hertogh G; Sagaert X; Coosemans W; Van Veer H; Renders A; Nafteux P
    Acta Chir Belg; 2016 Jun; 116(3):149-155. PubMed ID: 27472306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01).
    Yeo SG; Kim DY; Kim TH; Chang HJ; Oh JH; Park W; Choi DH; Nam H; Kim JS; Cho MJ; Kim JH; Park JH; Kang MK; Koom WS; Kim JS; Nam TK; Chie EK; Kim JS; Lee KJ
    Ann Surg; 2010 Dec; 252(6):998-1004. PubMed ID: 21107110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.